Epic Sciences unveils new liquid biopsy test to predict sensitivity to PARP inhibitors in prostate cancer trial
Epic Sciences and its research partners report the use of the company's new circulating tumor cell (CTC) homologous…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Apr 19
Epic Sciences and its research partners report the use of the company's new circulating tumor cell (CTC) homologous…
04 Apr 19
Antimicrobial Barrier Caps manufacturer Pursuit Vascular has received both Conformité Européene (CE) Mark and Medical Device Single Audit…
03 Apr 19
Bio-Rad Laboratories has secured approval from the US Food and Drug Administration (FDA) for its BioPlex 2200 Lyme…
27 Mar 19
Dune Medical Devices announced the completion of the first in-man cases for its percutaneous soft tissue biopsy device…
27 Mar 19
Curetis, a developer of next-level molecular diagnostic solutions, has entered into an exclusive long-term strategic distribution partnership with…
25 Mar 19
Akoya Biosciences has announced the full commercial release of new products that together form the most complete solution…
22 Mar 19
Switzerland-based healthcare company Roche has launched NAVIFY Mutation Profiler and NAVIFY Therapy Matcher to support comprehensive genomic profiling…
22 Mar 19
Harvard University has granted a worldwide exclusive license to Sherlock Biosciences to develop and commercialize technology from the…
21 Mar 19
SOTIO, a biotechnology company owned by the PPF Group, presented results from SOV02, its Phase II clinical trial…
21 Mar 19
A pancreatic cancer trial in the UK, which intends to match patients with more targeted and effective treatment…